|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 53.82 USD | +0.15% |
|
-0.96% | -18.17% |
| 12-03 | Leerink Partners Downgrades BioMarin Pharmaceutical to Market Perform From Outperform, Adjusts PT to $60 From $82 | MT |
| 11-21 | Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial | MT |
| Capitalization | 10.32B 8.86B 8.29B 7.74B 14.29B 928B 15.55B 96.12B 37.46B 440B 38.74B 37.92B 1,614B | P/E ratio 2025 * |
19.1x | P/E ratio 2026 * | 12.8x |
|---|---|---|---|---|---|
| Enterprise value | 9.03B 7.75B 7.25B 6.77B 12.5B 812B 13.6B 84.08B 32.76B 385B 33.89B 33.17B 1,412B | EV / Sales 2025 * |
2.85x | EV / Sales 2026 * | 2.46x |
| Free-Float |
99.12% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: BioMarin Pharmaceutical Inc.
| 1 day | +0.11% | ||
| 1 week | -0.96% | ||
| Current month | -3.83% | ||
| 1 month | +2.13% | ||
| 3 months | -1.30% | ||
| 6 months | -6.42% | ||
| Current year | -18.17% |
| 1 week | 52.55 |  | 54.66 |
| 1 month | 51.99 | | 56.45 |
| Current year | 50.76 | | 73.51 |
| 1 year | 50.76 | | 73.51 |
| 3 years | 50.76 | | 117.77 |
| 5 years | 50.76 | | 117.77 |
| 10 years | 50.76 | | 131.94 |
| Manager | Title | Age | Since |
|---|---|---|---|
Alexander Hardy
CEO | Chief Executive Officer | 56 | 30/11/2023 |
Brian Mueller
DFI | Director of Finance/CFO | 51 | 28/01/2020 |
Gregory Friberg
CTO | Chief Tech/Sci/R&D Officer | 51 | 29/09/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Randy Meier
CHM | Chairman | 65 | 30/11/2023 |
Willard Dere
BRD | Director/Board Member | 71 | 17/07/2016 |
Robert Hombach
BRD | Director/Board Member | 59 | 28/09/2017 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 3.45% | 1 M€ | 0.00% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.15% | -0.96% | -19.03% | -49.38% | 10.32B | |
| +2.82% | -1.64% | -8.57% | -4.13% | 71.06B | |
| -0.10% | -0.99% | -35.43% | -39.14% | 58.39B | |
| 0.00% | +1.00% | +34.26% | +235.55% | 53.56B | |
| +0.30% | +66.50% | +66.50% | +66.50% | 52.3B | |
| -0.07% | -3.17% | +11.96% | -39.77% | 25.8B | |
| -0.71% | -6.95% | +30.30% | +14.67% | 18.68B | |
| -1.07% | -11.03% | +113.55% | +158.91% | 18.59B | |
| -0.11% | -12.38% | +60.18% | +1,012.06% | 16.64B | |
| -0.04% | -.--% | +55.21% | +154.72% | 14.02B | |
| Average | +0.11% | -3.98% | +30.89% | +151.00% | 33.94B | |
| Weighted average by Cap. | +0.51% | -3.41% | +21.22% | +100.82% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 3.17B 2.72B 2.55B 2.38B 4.39B 285B 4.77B 29.51B 11.5B 135B 11.89B 11.64B 496B | 3.39B 2.91B 2.73B 2.55B 4.7B 305B 5.11B 31.6B 12.31B 145B 12.74B 12.47B 531B |
| Net income | 550M 473M 442M 413M 762M 49.48B 829M 5.13B 2B 23.45B 2.07B 2.02B 86.07B | 831M 713M 667M 623M 1.15B 74.68B 1.25B 7.74B 3.01B 35.4B 3.12B 3.05B 130B |
| Net Debt | -1.29B -1.11B -1.04B -970M -1.79B -116B -1.95B -12.04B -4.69B -55.1B -4.85B -4.75B -202B | -1.97B -1.69B -1.58B -1.48B -2.73B -177B -2.97B -18.37B -7.16B -84.07B -7.4B -7.25B -309B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/12/25 | 53.79 $ | +0.09% | 400,020 |
| 09/12/25 | 53.74 $ | +0.83% | 2,265,979 |
| 08/12/25 | 53.30 $ | -0.19% | 1,960,069 |
| 05/12/25 | 53.40 $ | -0.78% | 2,164,441 |
| 04/12/25 | 53.82 $ | -0.90% | 1,886,737 |
Delayed Quote Nasdaq, December 10, 2025 at 05:28 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- BMRN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition